Low Leverage / Conservative Balance SheetA debt-to-equity of 0.075 indicates conservative leverage and limited interest burden. This structural financial strength gives Spineway flexibility to fund R&D, commercial expansion or absorb reimbursement changes without major refinancing risk over the next several quarters.

Strong Revenue GrowthA nearly 70% year increase in revenue reflects strong product adoption and market penetration in spinal implants. Sustained top-line growth can deliver scale economies, support expanded clinical adoption and provide resources to address margins and commercial expansion over months.

Improving Gross MarginAn improved gross margin to 28.1% suggests better pricing, mix, or cost control at the product level. Structurally higher gross margins create room to absorb SG&A and R&D expenses and form a credible pathway toward sustainable operating profitability as sales scale.

Bears Say

Persistent Net LossesA deeply negative net margin erodes equity and limits reinvestable cash. Unless Spineway materially improves cost structure or pricing, ongoing losses will necessitate external funding, constrain long-term investment, and risk dilution or slowed commercial rollout over multiple quarters.

Weak Cash GenerationA 55% decline in free cash flow and negative operating cash conversion indicate structural liquidity pressure. Persistent weak cash generation forces reliance on financing for working capital and capex, increasing execution risk for commercialization and R&D over the medium term.

Negative Returns On EquityA negative ROE signals the company is not generating returns from shareholders' capital. Persistent negative ROE implies inefficient capital allocation and undermines ability to attract non-dilutive financing, complicating plans to scale and reach profitability in coming quarters.

ALSPW FAQ

What was Spineway SA’s price range in the past 12 months?

Spineway SA lowest stock price was €0.09 and its highest was €0.26 in the past 12 months.

What is Spineway SA’s market cap?

Spineway SA’s market cap is €6.80M.

When is Spineway SA’s upcoming earnings report date?

Spineway SA’s upcoming earnings report date is Nov 03, 2026 which is in 256 days.

How were Spineway SA’s earnings last quarter?

Spineway SA released its earnings results on Feb 17, 2026. The company reported -€0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.023.

Is Spineway SA overvalued?

According to Wall Street analysts Spineway SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spineway SA pay dividends?

Spineway SA does not currently pay dividends.

What is Spineway SA’s EPS estimate?

Spineway SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spineway SA have?

Spineway SA has 35,544,390 shares outstanding.

What happened to Spineway SA’s price movement after its last earnings report?

Spineway SA reported an EPS of -€0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.521%.

Which hedge fund is a major shareholder of Spineway SA?

Currently, no hedge funds are holding shares in FR:ALSPW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spineway SA

Spineway SA engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column. The company offers ayers rock, an anterior cervical interbody fusion cage; blue mountain, an anterior cervical interbody fusion plate; mont blanc, a posterior thoracolumbar pedicle screws; mont blanc baby, a pediatric growing rod system; mont blanc 3d+, a coplanar alignment system; kili, an anterior lumbar interbody fusion cage; twin peaks plif bullet shaped posterior lumbar interbody fusion cages; twin peaks olif graft vascularization interbody fusion cages; twin peaks tlif transforaminal lumbar interbody fusion cages; and mont blanc mis, a mini-invasive thoracolumbar system. It also provides sonora, a biomaterial for bone regeneration. In addition, the company exports its products. Spineway SA was incorporated in 2005 and is headquartered in Ecully, France.